AN EXPLORATION OF FACTORS THAT MAY INFLUENCE RACIAL AND ETHNIC DIVERSITY IN CLINICAL TRIAL POPULATIONS IN THE US FOOD AND DRUG ADMINISTRATION'S (FDA) DRUG TRIALS SNAPSHOTS.

被引：0
|
作者：
Chege, W. [1 ]
Suleyman, S. [2 ]
Shepherd, J. [1 ]
Watson, P. [1 ]
Poddar, A. [1 ]
Omokaro, S. [1 ]
Fienkeng, M. [1 ]
Crentsil, V. [1 ]
Budashewitz, P. [1 ]
ElZarrad, M. [1 ]
机构：
[1] US FDA, Silver Spring, MD USA
[2] GlaxoSmithKline, Rockville, MD USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PW-009
引用
收藏
页码：S71 / S71
页数：1
相关论文
共 22 条
  • [1] Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in US Food and Drug Administration Drug Approvals From 2000 to 2020
    Berkowitz, Sean T.
    Groth, Sylvia L.
    Gangaputra, Sapna
    Patel, Shriji
    JAMA OPHTHALMOLOGY, 2021, 139 (06) : 629 - 637
  • [2] The US Food and Drug Administration's Efforts to Support Ophthalmology Clinical Trials
    Eydelman, Malvina B.
    JAMA OPHTHALMOLOGY, 2014, 132 (12) : 1391 - 1392
  • [3] Timing of US Food and Drug Administration (FDA) cancer drug approvals relative to publication of clinical trial results.
    Khaki, Ali Raza
    Desai, Aakash
    Schoen, Martin W.
    Gyawali, Bishal
    Chen, Eddy J.
    Yang, Peter C.
    Warner, Jeremy Lyle
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020
    M. P. Lythgoe
    J. Krell
    P. Savage
    V. Prasad
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 1208 - 1211
  • [5] Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006-2020
    Lythgoe, M. P.
    Krell, J.
    Savage, P.
    Prasad, V.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1208 - 1211
  • [6] Considering Modifications to Existing FDA Regulatory Incentives to Achieve Greater Racial and Ethnic Diversity in Pivotal Clinical Trials for Drug Approvals
    Schick, Sarah Thompson
    Axelsen, Kirsten
    FOOD AND DRUG LAW JOURNAL, 2022, 77 (02) : 246 - 264
  • [7] US FOOD AND DRUG ADMINISTRATION (FDA) EXPERIENCE WITH ADULT AND PEDIATRIC COMBINED CLINICAL TRIALS UNDER PREA AND BPCA.
    Park, K.
    Tanaudommongkon, I.
    Wu, J.
    Kim, C.
    Green, D.
    Burckart, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S105 - S106
  • [8] FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the US Food and Drug Administration.
    Singh, Harpreet
    Kanapuru, Bindu
    Smith, Che
    Fashoyin-Aje, Lola A.
    Myers, Adrian
    Kim, Geoffrey
    Pazdur, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Magnitude of clinical benefit of trials supporting US Food and Drug Administration (FDA) approval of breakthrough and non-breakthrough drugs
    Molto Valiente, C.
    Borrell, M.
    Hwang, T.
    Gich Saladich, I.
    Barnadas, A.
    Amir, E.
    Kesselheim, A.
    Tibau, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Gender and Ethnicity of Enrolled Participants in US Food and Drug Administration (FDA) Clinical Trials for Approved Ophthalmological New Molecular Entities
    Birnbaum, Faith A.
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2018, 110 (05) : 473 - 479
123